Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zenas BioPharma (ZBIO) Change in Cash (2023 - 2025)

Zenas BioPharma has reported Change in Cash over the past 3 years, most recently at -$4.9 million for Q4 2025.

  • Quarterly results put Change in Cash at -$4.9 million for Q4 2025, up 87.78% from a year ago — trailing twelve months through Dec 2025 was -$209.2 million (down 179.57% YoY), and the annual figure for FY2025 was -$209.2 million, down 179.57%.
  • Change in Cash for Q4 2025 was -$4.9 million at Zenas BioPharma, down from $71.6 million in the prior quarter.
  • Over the last five years, Change in Cash for ZBIO hit a ceiling of $176.1 million in Q3 2024 and a floor of -$152.5 million in Q2 2025.
  • Median Change in Cash over the past 3 years was -$15.5 million (2023), compared with a mean of $4.2 million.
  • Peak annual rise in Change in Cash hit 87.78% in 2025, while the deepest fall reached 525.71% in 2025.
  • Zenas BioPharma's Change in Cash stood at -$15.5 million in 2023, then tumbled by 160.74% to -$40.3 million in 2024, then skyrocketed by 87.78% to -$4.9 million in 2025.
  • The last three reported values for Change in Cash were -$4.9 million (Q4 2025), $71.6 million (Q3 2025), and -$152.5 million (Q2 2025) per Business Quant data.